US 12,171,880 B2
Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof
Chao-Yi Chen, New Taipei (TW); and Chih-Chia Tsai, New Taipei (TW)
Assigned to Taiwan Mercury Medical Corporation, New Taipei (TW)
Filed by Taiwan Mercury Medical Corporation, New Taipei (TW)
Filed on Sep. 8, 2022, as Appl. No. 17/940,746.
Prior Publication US 2024/0082163 A1, Mar. 14, 2024
Int. Cl. A61K 9/20 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/2054 (2013.01) [A61K 9/0056 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2036 (2013.01); A61K 9/2077 (2013.01)] 1 Claim
 
1. A metformin tablet for relieving pain and reducing inflammation, comprising:
a filler comprising microcrystalline cellulose and silicified microcrystalline cellulose;
a diluent comprising mannitol and a sugar alcohol;
an excipient comprising polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG);
a binder comprising glucose and lactose;
a slow-release agent comprising at least one of polylactic acid;
a sweetener comprising isomalt;
a medicinal powder comprising metformin and the excipient;
a disintegrant; and
a lubricant;
wherein the metformin tablet comprises a hollow part, a first colloidal layer formed on an outer surface of the hollow part, and a second colloidal layer formed on an outer surface of the first colloidal layer;
wherein the first colloidal layer is thicker than the second colloidal layer, and is composed of a mixture of the filler having 2% to 22% by weight of the first colloidal layer, the diluent having 3% to 24% by weight of the first colloidal layer, the excipient having 1% to 25% by weight of the first colloidal layer, the binder having 0.5% to 18% by weight of the first colloidal layer, the slow-release agent having 0.1% to 12% by weight of the first colloidal layer, and the sweetener having 1% to 22% by weight of the first colloidal layer; and
the second colloidal layer of the tablet is composed of a mixture of the filler having 2% to 22% by weight of the second colloidal layer, the diluent having 3% to 24% by weight of the second colloidal layer, the excipient having 1% to 25% by weight of the second colloidal layer, the binder having 0.5% to 18% by weight of the second colloidal layer, the slow-release agent having 0.1% to 12% by weight of the second colloidal layer, the sweetener having 1% to 22% by weight of the second colloidal layer, and the medicinal powder.